Bioventus, UnitedHealthcare agree to commercial contract for HA-based products

Written by Alan Condon | September 09, 2019 | Print  |

Orthobiologic company Bioventus signed a nationwide contract with UnitedHealthcare employer and individual commercial plans this week.

Three things to know:

1. Bioventus’ Durolane and Gelsyn-3 treatments for knee osteoarthritis pain will be made available to UnitedHealth commercial plan members starting Oct. 1.

2. Durolane is a single-injection and Gelsyn-3 is a three-injection hyaluronic acid-based joint fluid treatment.

3. Bioventus plans to expand Durolane into Australia and New Zealand and is launching Durolane SJ — another HA-based product — in both countries later this year.

More articles on devices:
'A dream come true': Dr. Jorge Chahla strives for success at Rush
New York hospital invests $2M in imaging system for spine, brain — 4 things to know
What Stryker's spine division stands to gain from 5 acquisitions 



© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months